The Journal of Clinical Endocrinology & Metabolism · 2019 · 56 citations · 28 references
Public HealthBiostatisticsGeriatric MedicineEpidemiologic MethodsEpidemiologySurvival AnalysisCardiovascular DiseaseMortality AnalysisMortality ModelingMortality Risk AssessmentCause-specific Mortality AnalysisCox RegressionOld-age Mortality EstimationProspective Cohort Data
CONTEXT: The patterns of the association between high-density lipoprotein cholesterol (HDL-C) concentrations and mortality among the elderly are still unclear. OBJECTIVE: To examine the association of HDL-C concentrations with mortality and to identify the optimal HDL-C concentration range that predicts the lowest risk of all-cause mortality among the elderly. DESIGN: This was a nationwide, community-based, prospective cohort study. PARTICIPANTS: This study included 7766 elderly individuals (aged ≥65 years; mean age: 74.4 years) from the Health and Retirement Study. Cox proportional hazards models and Cox models with penalized smoothing splines were used to estimate hazard ratios (HRs) with 95% CI for all-cause and cause-specific mortality. RESULTS: During a median follow-up of 5.9 years, 1921 deaths occurred. After a full adjustment for covariates, a nonlinear (P < 0.001 for nonlinearity) association was found between HDL-C and all-cause mortality [minimum mortality risk at 71 mg/dL (1.84 mM)]; the risk for all-cause mortality was significantly higher in the groups with HDL-C concentration <61 mg/dL (1.58 mM; HR: 1.18; 95% CI: 1.05 to 1.33) and with HDL-C concentration >87 mg/dL (2.25 mM; HR: 1.56; 95% CI: 1.17 to 2.07) than in the group with HDL-C concentrations ranging from 61 to 87 mg/dL (1.58 to 2.25 mM). Nonlinear associations of HDL-C concentrations with both cardiovascular and noncardiovascular mortality were also observed (both P < 0.001 for nonlinearity). CONCLUSIONS: Among the elderly, nonlinear associations were found between HDL-C and all-cause and cardiovascular mortality. The single optimal HDL-C concentration and range were 71 mg/dL and 61 to 87 mg/dL, respectively.
28
Joep Perk, Guy De Backer, H. Gohlke et al. · European Heart Journal · 2012 · 8.5K citations · Full text
2016 European Guidelines on cardiovascular disease prevention in clinical practice
Massimo Piepoli, Arno W. Hoes, Stefan Agewall et al. · European Heart Journal · 2016 · 6.5K citations · Full text
Effects of Torcetrapib in Patients at High Risk for Coronary Events
Philip J. Barter, Mark J. Caulfield, Mats Eriksson et al. · New England Journal of Medicine · 2007 · 3.1K citations · Full text
Medicine, Cardiology, Pharmacology +14